Phase 2 Trial for Alveolar Soft Part Sarcoma in Patients Aged 14 and Older
Summary
A Phase II single-arm multicenter clinical study (NCT07548177) is investigating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma. The trial evaluates objective response rate as the primary endpoint. This study represents a targeted combination therapy approach for a rare sarcoma subtype, potentially expanding treatment options for this patient population.
“This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The National Institutes of Health registered a new Phase II clinical trial (NCT07548177) on ClinicalTrials.gov for a combination therapy targeting alveolar soft part sarcoma. The study will evaluate benmelstobart injection and anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable disease, measuring objective response rate as the primary endpoint.
For pharmaceutical sponsors, clinical investigators, and healthcare providers, this trial registration signals ongoing research activity in the rare sarcoma space. Organizations conducting similar oncology research may find opportunities for peer-collaboration or competitive intelligence monitoring. Patients and advocacy groups may benefit from tracking trial progress through ClinicalTrials.gov for potential enrollment eligibility.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
Phase 2 NCT07548177 Kind: PHASE2 Apr 23, 2026
Abstract
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).
Conditions: Alveolar Soft Part Sarcoma
Interventions: Benmelstobart injection combined with Anlotinib hydrochloride capsule
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.